OKYO Pharma (OKYO) Change in Receivables (2024 - 2026)

OKYO Pharma's (OKYO) quarterly Change in Receivables came in at $101317.0 in Q1 2026, up 13.16% quarter-over-quarter from $89536.0 in Q4 2025.

Analysis

OKYO Pharma (OKYO) Change in Receivables (2024 - 2026) Analysis & Trends

OKYO Pharma (OKYO) has reported Change in Receivables for 3 consecutive years, with $101317.0 the latest figure, recorded in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn	1.09 Bn
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn	333.00 Mn
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn	140.20 Mn
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn	838.50 Mn
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn	-
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn	-53.00 Mn
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn	31.60 Mn
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn	269.40 Mn
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn	37.16 Mn
10	OKYO Pharma	1.06 Bn	1.06 Bn	-	101,317.00

Historic Data

Download Data